H. Lundbeck A/S/€HLUNB

H. Lundbeck shares fall as the Lundbeck Foundation’s voluntary A-to-B share exchange offer nears its 16 September deadline, increasing expected B-share supply and selling pressure.
9 hours agoLightyear AI
1D1W1MYTD1Y5YMAX

About H. Lundbeck A/S

H. Lundbeck A/S is a Danish pharmaceutical company focused on the research, development, production, and marketing of pharmaceuticals for the treatment of brain disorders. Headquartered in Copenhagen, Denmark, Lundbeck's core business includes a portfolio of products addressing conditions such as depression, anxiety, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company has a significant presence in the neuropharmaceuticals industry, striving to deliver innovative solutions to patients with unmet medical needs. Lundbeck operates internationally, distributing its products across multiple markets, supported by its strategic positioning in research and development. Unique competitive strengths include its dedicated focus on central nervous system disorders and ongoing investments in innovative therapies.
Ticker
€HLUNB
Sector
Health
Primary listing
XGAT
Employees
5,000
Headquarters
Valby, Denmark
Website
www.lundbeck.com

H. Lundbeck A/S Metrics

BasicAdvanced
€5.9B
11.32
€0.53
0.26
€0.15
2.56%

Bulls say / Bears say

Commercial momentum is strong: first-half revenue rose 16% at constant exchange rates, led by Vyepti growth of 46% and Rexulti growth of 17%. Lundbeck maintained 2026 guidance for 7–9% revenue growth and 8–14% adjusted EBITDA growth. (Lundbeck)
Lundbeck is approaching important pipeline catalysts in high-need neurological diseases. Bexicaserin has reached the last-patient milestone in its Phase III DEEp OCEAN trial, with headline results expected by the end of 2026 or early 2027, while its oral orexin agonist has received FDA Fast Track status. (Lundbeck, Lundbeck)
Financial resilience has improved materially. First-half adjusted EBITDA rose 19% at constant exchange rates, free cash flow was DKK 2.3 billion, and net debt to EBITDA fell to 1.0 times from 1.8 times a year earlier, giving Lundbeck more room to invest or pursue deals. (Quartr, Lundbeck)
Revenue growth is becoming concentrated in Vyepti and Rexulti, while Brintellix/Trintellix was broadly flat at constant exchange rates in the first half. That leaves the business more exposed to maturity and generic competition in older products. (Lundbeck, LegalClarity)
The first-half headline growth included a planned DKK 470 million inventory build in partner markets. That benefit will unwind in the second half, while higher research and development spending and other costs are already limiting underlying profit growth. (Lundbeck, Quartr)
The pipeline offers catalysts, but it remains clinically unproven. Bexicaserin has only completed Phase III recruitment, while the orexin programme is still in Phase Ib and regulatory designations do not establish efficacy or safety. (Lundbeck, Lundbeck)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.

Funds containing H. Lundbeck A/S

AllGBPEURUSD
Funds
Fund name
Fund size
€HLUNB weighting
WisdomTree Global Quality Dividend Growth£GGRG
£1.9B0.03%
Vanguard FTSE Developed Europe€VWCG
€3.1B0.01%
Vanguard FTSE Developed Europe€VEUR
€4.8B0.01%
Vanguard FTSE Developed Europe£VEUR
£4.1B0.01%
Vanguard FTSE Developed Europe£VEUA
£2.6B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.